Human papillomavirus type 18 L1 capsid protein antigen

DB10302ApprovedInvestigationalVaccinesInactivated Human Papillomavirus Vaccine

Human papillomavirus type 18 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. It is... It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18.

First approval
Canada, 2006 · United States, 2006 · European Union, 2020
Also known as
L1 protein, Human papillomavirus type 18 Vaccine · Recombinant human papillomavirus type 18 L1 protein
Brand names
  • Cervarix
  • Gardasil
  • Gardasil 9

Resolves to

Compound
UNIIJ2D279PEM5
Clinical / RWD
RxNorm798266

What you can answer from here — as of April 02, 2025

197Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
93Marketed productsAcross 10 countries and 17 labellers
Sign in

Which other approved drugs treat the same conditions as Human papillomavirus type 18 L1 capsid protein antigen, and which companies have late-stage candidates in those indications?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In